These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 24126432

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, Naudet F.
    Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
    [Abstract] [Full Text] [Related]

  • 23. Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
    Higuchi S, Takahashi M, Murai Y, Tsuneyoshi K, Nakamura I, Meulien D, Miyata H.
    Psychiatry Clin Neurosci; 2020 Aug; 74(8):431-438. PubMed ID: 32359104
    [Abstract] [Full Text] [Related]

  • 24. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.
    Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E.
    Alcohol Clin Exp Res; 1994 Oct; 18(5):1162-7. PubMed ID: 7847600
    [Abstract] [Full Text] [Related]

  • 25. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
    Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB.
    Arch Gen Psychiatry; 1999 Aug; 56(8):719-24. PubMed ID: 10435606
    [Abstract] [Full Text] [Related]

  • 26. Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.
    Costantini LC, Kleppner SR, McDonough J, Azar MR, Patel R.
    Int J Pharm; 2004 Sep 28; 283(1-2):35-44. PubMed ID: 15363499
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. ▼Nalmefene for alcohol dependence.
    Drug Ther Bull; 2014 May 28; 52(5):54-7. PubMed ID: 24809337
    [Abstract] [Full Text] [Related]

  • 29. Pharmacotherapy of alcoholism - an update on approved and off-label medications.
    Soyka M, Müller CA.
    Expert Opin Pharmacother; 2017 Aug 28; 18(12):1187-1199. PubMed ID: 28658981
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Benefits in reducing alcohol consumption: how nalmefene can help].
    Bendimerad P, Blecha L.
    Encephale; 2014 Dec 28; 40(6):495-500. PubMed ID: 25454365
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Alcohol dependence and opioid receptor -Pharmacological profile of nalmefene].
    Ohgi Y.
    Nihon Yakurigaku Zasshi; 2020 Dec 28; 155(3):145-148. PubMed ID: 32378631
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Pharmacological profile and clinical findings of nalmefene (Selincro®) for reducing alcohol consumption in patients with alcohol dependence].
    Tadori Y.
    Nihon Yakurigaku Zasshi; 2020 Dec 28; 155(2):113-119. PubMed ID: 32115477
    [Abstract] [Full Text] [Related]

  • 39. Severe opioid withdrawal syndrome after a single dose of nalmefene.
    Donnerstag N, Schneider T, Lüthi A, Taegtmeyer A, Raetz Bravo A, Mehlig A.
    Eur J Clin Pharmacol; 2015 Aug 28; 71(8):1025-6. PubMed ID: 26050241
    [No Abstract] [Full Text] [Related]

  • 40. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
    Lobmaier PP, Kunøe N, Gossop M, Waal H.
    CNS Neurosci Ther; 2011 Dec 28; 17(6):629-36. PubMed ID: 21554565
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.